IGHE and Kallmann syndrome: At six months after dupilumab therapy, there were no significant differences between those with and without NP with regards to clinical (anosmia, ACT, OCs use, and SNOTT22 score), laboratory parameters (eosinophilic count, serum IgE level), and FEV1%.